173 related articles for article (PubMed ID: 36477181)
21. Outcomes in patients with
Aglietta M; Chiarion-Sileni V; Fava P; Guidoboni M; Depenni R; Minisini A; Consoli F; Ascierto PA; Rinaldi G; Banzi M; Marconcini R; Gueli R; Ferraresi V; Tucci M; Tonini G; Lo Re G; Guida M; Del Vecchio M; Marcon IG; Queirolo P
Tumori; 2023 Dec; 109(6):537-545. PubMed ID: 37417313
[TBL] [Abstract][Full Text] [Related]
22. Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib.
Saiag P; Robert C; Grob JJ; Mortier L; Dereure O; Lebbe C; Mansard S; Grange F; Neidhardt EM; Lesimple T; Machet L; Bedane C; Maillard H; Dalac-Rat S; Nardin C; Szenik A; Denden A; Dutriaux C
Eur J Cancer; 2021 Sep; 154():57-65. PubMed ID: 34243078
[TBL] [Abstract][Full Text] [Related]
23. Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers.
Schadendorf D; Robert C; Dummer R; Flaherty KT; Tawbi HA; Menzies AM; Banerjee H; Lau M; Long GV
Eur J Cancer; 2021 Aug; 153():234-241. PubMed ID: 34225229
[TBL] [Abstract][Full Text] [Related]
24. A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAF
Dayimu A; Gupta A; Matin RN; Nobes J; Board R; Payne M; Rao A; Fusi A; Danson S; Eccles B; Carser J; Brown CO; Steven N; Bhattacharyya M; Brown E; Gonzalez M; Highley M; Pickering L; Kumar S; Waterston A; Burghel G; Demain L; Baker E; Wulff J; Qian W; Twelves S; Middleton M; Corrie P
Eur J Cancer; 2024 Jan; 196():113455. PubMed ID: 38029480
[TBL] [Abstract][Full Text] [Related]
25. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF
Schreuer M; Jansen Y; Planken S; Chevolet I; Seremet T; Kruse V; Neyns B
Lancet Oncol; 2017 Apr; 18(4):464-472. PubMed ID: 28268064
[TBL] [Abstract][Full Text] [Related]
26. Retrospective Chart Review of Dabrafenib Plus Trametinib in Patients with Metastatic BRAF V600-Mutant Melanoma Treated in the Individual Patient Program (DESCRIBE Italy).
Aglietta M; Chiarion-Sileni V; Fava P; Guidoboni M; Depenni R; Minisini A; Consoli F; Ascierto P; Rinaldi G; Banzi M; Marconcini R; Gueli R; Ferraresi V; Tucci M; Tonini G; Lo Re G; Guida M; Del Vecchio M; Marcon IG; Queirolo P
Target Oncol; 2021 Nov; 16(6):789-799. PubMed ID: 34755244
[TBL] [Abstract][Full Text] [Related]
27. Dabrafenib plus Trametinib: a Review in Advanced Melanoma with a BRAF (V600) Mutation.
Dhillon S
Target Oncol; 2016 Jun; 11(3):417-28. PubMed ID: 27246822
[TBL] [Abstract][Full Text] [Related]
28. Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.
Long GV; Weber JS; Infante JR; Kim KB; Daud A; Gonzalez R; Sosman JA; Hamid O; Schuchter L; Cebon J; Kefford RF; Lawrence D; Kudchadkar R; Burris HA; Falchook GS; Algazi A; Lewis K; Puzanov I; Ibrahim N; Sun P; Cunningham E; Kline AS; Del Buono H; McDowell DO; Patel K; Flaherty KT
J Clin Oncol; 2016 Mar; 34(8):871-8. PubMed ID: 26811525
[TBL] [Abstract][Full Text] [Related]
29. An open label, non-randomised, phase IIIb study of trametinib in combination with dabrafenib in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: A subgroup analysis of patients with brain metastases.
Dutriaux C; Robert C; Grob JJ; Mortier L; Dereure O; Lebbe C; Mansard S; Grange F; Neidhardt EM; Lesimple T; Machet L; Bedane C; Maillard H; Dalac-Rat S; Nardin C; Szenik A; Denden A; Saiag P
Eur J Cancer; 2022 Nov; 175():254-262. PubMed ID: 36170791
[TBL] [Abstract][Full Text] [Related]
30. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.
Chen G; McQuade JL; Panka DJ; Hudgens CW; Amin-Mansour A; Mu XJ; Bahl S; Jané-Valbuena J; Wani KM; Reuben A; Creasy CA; Jiang H; Cooper ZA; Roszik J; Bassett RL; Joon AY; Simpson LM; Mouton RD; Glitza IC; Patel SP; Hwu WJ; Amaria RN; Diab A; Hwu P; Lazar AJ; Wargo JA; Garraway LA; Tetzlaff MT; Sullivan RJ; Kim KB; Davies MA
JAMA Oncol; 2016 Aug; 2(8):1056-64. PubMed ID: 27124486
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of dabrafenib and trametinib in combination as adjuvant treatment of BRAF V600E/K mutation-positive melanoma from a US healthcare payer perspective.
Gerbasi ME; Stellato D; Ghate SR; Ndife B; Moynahan A; Mishra D; Gunda P; Koruth R; Delea TE
J Med Econ; 2019 Dec; 22(12):1243-1252. PubMed ID: 31223037
[No Abstract] [Full Text] [Related]
32. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.
Amaria RN; Prieto PA; Tetzlaff MT; Reuben A; Andrews MC; Ross MI; Glitza IC; Cormier J; Hwu WJ; Tawbi HA; Patel SP; Lee JE; Gershenwald JE; Spencer CN; Gopalakrishnan V; Bassett R; Simpson L; Mouton R; Hudgens CW; Zhao L; Zhu H; Cooper ZA; Wani K; Lazar A; Hwu P; Diab A; Wong MK; McQuade JL; Royal R; Lucci A; Burton EM; Reddy S; Sharma P; Allison J; Futreal PA; Woodman SE; Davies MA; Wargo JA
Lancet Oncol; 2018 Feb; 19(2):181-193. PubMed ID: 29361468
[TBL] [Abstract][Full Text] [Related]
33. Interim analysis for post-marketing surveillance of dabrafenib and trametinib combination therapy in Japanese patients with unresectable and metastatic melanoma with BRAF V600 mutation.
Teshima Y; Kizaki M; Kurihara R; Kano R; Harumiya M
Int J Clin Oncol; 2020 Oct; 25(10):1870-1878. PubMed ID: 32699976
[TBL] [Abstract][Full Text] [Related]
34. Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.
Dummer R; Hauschild A; Santinami M; Atkinson V; Mandalà M; Kirkwood JM; Chiarion Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Schachter J; Lesimple T; Plummer R; Dasgupta K; Gasal E; Tan M; Long GV; Schadendorf D
N Engl J Med; 2020 Sep; 383(12):1139-1148. PubMed ID: 32877599
[TBL] [Abstract][Full Text] [Related]
35. Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma.
Schadendorf D; Amonkar MM; Stroyakovskiy D; Levchenko E; Gogas H; de Braud F; Grob JJ; Bondarenko I; Garbe C; Lebbe C; Larkin J; Chiarion-Sileni V; Millward M; Arance A; Mandalà M; Flaherty KT; Nathan P; Ribas A; Robert C; Casey M; DeMarini DJ; Irani JG; Aktan G; Long GV
Eur J Cancer; 2015 May; 51(7):833-40. PubMed ID: 25794603
[TBL] [Abstract][Full Text] [Related]
36. Dabrafenib plus trametinib in unselected advanced BRAF V600-mut melanoma: a non-interventional, multicenter, prospective trial.
Richtig E; Nguyen VA; Koelblinger P; Wolf I; Kehrer H; Saxinger W; Ressler JM; Weinlich G; Meyersburg D; Hafner C; Jecel-Grill E; Kofler J; Lange-Asschenfeldt B; Weihsengruber F; Rappersberger K; Svastics N; Gasser K; Seeber A; Kratochvill F; Nagler S; Mraz B; Hoeller C
Melanoma Res; 2024 Apr; 34(2):142-151. PubMed ID: 38092013
[TBL] [Abstract][Full Text] [Related]
37. Safety of combining dabrafenib plus trametinib in elderly BRAF V600 mutation-positive advanced melanoma patients: real-world data analysis of Spanish patients (ELDERLYMEL).
González-Barrallo I; Castellón Rubio VE; Medina J; España S; Mujika K; Majem M; Aguado C; Cabrera Suárez MÁ; Palacio I; Osterloh L; Martínez-Fernández A; García-Castaño A
Melanoma Res; 2022 Oct; 32(5):343-352. PubMed ID: 35762583
[TBL] [Abstract][Full Text] [Related]
38. Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases.
Hilbers ML; Dimitriou F; Lau P; Bhave P; McArthur GA; Zimmer L; Kudura K; Gérard CL; Levesque MP; Michielin O; Dummer R; Cheng PF; Mangana J
Eur J Cancer; 2021 Oct; 156():149-163. PubMed ID: 34454317
[TBL] [Abstract][Full Text] [Related]
39. Phase II Trial of Dabrafenib Plus Trametinib in Relapsed/Refractory
Hargrave DR; Terashima K; Hara J; Kordes UR; Upadhyaya SA; Sahm F; Bouffet E; Packer RJ; Witt O; Sandalic L; Kieloch A; Russo M; Cohen KJ;
J Clin Oncol; 2023 Nov; 41(33):5174-5183. PubMed ID: 37643378
[TBL] [Abstract][Full Text] [Related]
40. Cost-Effectiveness Analysis of Dabrafenib Plus Trametinib and Vemurafenib as First-Line Treatment in Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma in China.
Gao T; Liu J; Wu J
Int J Environ Res Public Health; 2021 Jun; 18(12):. PubMed ID: 34201096
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
